期刊
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
卷 79, 期 4, 页码 444-455出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FJC.0000000000001208
关键词
mTOR; vascular smooth muscle cells; proliferation; vascular proliferative diseases; mTOR inhibition
资金
- National Natural Science Foundation of China [81600040, 31871169]
- Innovation Guidance Project of Hunan [2018SK51606, 2018SK51704]
- Natural Science Foundation of the Province of Hunan [2021JJ30601, 2020JJ8032]
mTOR plays a key role in vascular proliferative diseases, and mTOR inhibitors show promise as a treatment option for these diseases.
The abnormal proliferation of vascular smooth muscle cells (VSMCs) is a key pathological characteristic of vascular proliferative diseases. Mammalian target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine kinase that plays an important role in regulating cell growth, motility, proliferation, and survival, as well as gene expression in response to hypoxia, growth factors, and nutrients. Increasing evidence shows that mTOR also regulates VSMC proliferation in vascular proliferative diseases and that mTOR inhibitors, such as rapamycin, effectively restrain VSMC proliferation. However, the molecular mechanisms linking mTOR to vascular proliferative diseases remain elusive. In our review, we summarize the key roles of the mTOR and the recent discoveries in vascular proliferative diseases, focusing on the therapeutic potential of mTOR inhibitors to target the mTOR signaling pathway for the treatment of vascular proliferative diseases. In this study, we discuss mTOR inhibitors as promising candidates to prevent VSMC-associated vascular proliferative diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据